



September 30, 2004

FROM:

Padilla Speer Beardsley Inc.
1101 West River Parkway
Minneapolis, Minn. 55415

FOR:

CHF Solutions Inc.
7601 Northland Drive, Suite 170
Brooklyn Park, Minn. 55428

Nancy Johnson/Laura Spitzack
(612) 455-1745/(612) 455-1782

John Erb, CEO/President
(763) 463-4600

FOR IMMEDIATE RELEASE

CHF SOLUTIONS CLINICAL RESULTS PRESENTED AT THE SCIENTIFIC MEETING OF THE HEART FAILURE SOCIETY OF AMERICA

Encouraging Results Stimulate Launch of Large Randomized Clinical Trial Designed to Compare Company's Aquapheresis™ Therapy with Standard Fluid Removal Treatment Options

BROOKLYN PARK, MINN. – SEPTEMBER 30, 2004 – CHF Solutions, Inc., a private medical device manufacturer, announced today that new findings from two clinical trials of Aquapheresis™, the company's therapy for fluid overload, were presented as posters at the recent Scientific Meeting of the Heart Failure Society of America (HFSA) in Toronto, Canada. Data from the EUPHORIA trial at Midwest Heart Specialists, Chicago, and the RAPID CHF study, conducted by the Minnesota Heart Failure Consortium (MHFC), Minneapolis, both demonstrated clear clinical benefits of Aquapheresis. Administered via CHF Solutions' Aquadex™ System 100, Aquapheresis is designed to safely and predictably remove excess fluid from fluid-overloaded patients. In heart failure patients, an inefficient heart can lead to a buildup of excess fluid, causing swollen legs and arms, fatigue, and eventually severe and life-threatening shortness of breath.

"These studies are important steps in broadening awareness of Aquapheresis as a treatment that can help the large and growing heart failure population," said John L. Erb, CHF Solutions president and chief executive officer. "We are pleased to see these studies confirm the efficacy of the Aquadex System 100 and are committing to expanding our knowledge of this therapy approach."

"Both the EUPHORIA and RAPID CHF trial results add to the growing clinical evidence of the acute clinical benefits of fluid removal using Aquapheresis and support the sustained clinical benefits as seen in previous literature on ultrafiltration," said Paul Sobotka, M.D., chief medical officer at CHF Solutions. "With next year's completion of our ongoing multi-center, prospective, randomized UNLOAD trial, we expect to confirm the benefits shown in smaller trials on a much wider scale."

(more)

The EUPHORIA Trial - Midwest Heart Specialists

The results of the EUPHORIA (Early Ultrafiltration Therapy in Patients with Decompensated Heart Failure and Observed Resistance to Interventions with Diuretic Agents) trial demonstrated that early treatment with the CHF Solutions Aquadex System 100 facilitated discharge of 68 percent of hospitalized patients admitted with acutely decompensated heart failure and diuretic resistance in three days or less. These patients exhibited significant declines in brain natriuretic peptide (BNP) levels indicating decreased stress level of their hearts and improvement on the Quality Of Life and NYHA (New York Heart Association) classification scales. In follow-up, none of the patients were readmitted within 30 days and only two admissions occurred within 90 days, one for elective pacemaker implantation and the other for dehydration associated with an incidental infection.

“In the trial, this removal of large amounts of fluid was achieved without hypotension, worsening renal failure or electrolytes abnormalities,” said principal investigator of the EUPHORIA study, Maria Rosa Costanzo, M.D., Midwest Heart Specialists. “The beneficial neurohormonal and clinical changes of early Aquapheresis were sustained up to 90 days.”

The RAPID CHF Clinical Study - Minnesota Heart Failure Consortium

The RAPID CHF (Relief for Acutely Fluid Overloaded Patients with Decompensated Congestive Heart Failure) clinical trial is the first randomized trial of ultrafiltration therapy for acute heart failure patients ever performed. The results demonstrated that patients hospitalized for CHF treated with a single, eight-hour Aquapheresis session, in addition to standard medical therapy, achieved significantly greater volume removal 24 hours after enrollment compared to patients receiving standard medical therapy alone.

"Our results show that Aquapheresis is feasible in a community-based hospital setting and is a safe and effective means of fluid removal in patients hospitalized with CHF," said Dr. Bradley Bart, principal investigator of the RAPID CHF study and director of Nuclear Cardiac Imaging at Hennepin County Medical Center, Minneapolis.

The RAPID CHF study assessed several measures of clinical efficacy, including total weight loss, quality of life, level of CHF disease classification, length of hospital stay and blood chemistry changes before, during and 30 days after treatment. This study was conducted at six Minneapolis/St.Paul-based hospitals.

(more)

The UNLOAD Trial - 20 Clinical Sites

The UNLOAD (Ultrafiltration versus IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart Failure) trial is comparing the long-term safety and efficacy of Aquapheresis to conventional intravenous diuretics in hospitalized heart failure patients with fluid overload. This trial will enroll 200 patients at as many as 20 U.S. clinical sites. CHF Solutions expects to announce UNLOAD trial results in the fourth quarter of 2005.

About Aquapheresis™ and the Aquadex™ System 100

Aquapheresis, an advanced form of ultrafiltration, is a simple, transportable procedure that can be performed in virtually any clinical setting and remove up to four liters (one gallon) of excess fluid from the body in eight hours with no clinically significant impact on electrolytes, heart rate or blood chemistry. Performed by the Aquadex System 100, this procedure is highly automated and easy to use. Standard catheters inserted into peripheral or central veins connect the fluid-overloaded patient to the Aquadex System 100.

Aquapheresis with the Aquadex System 100 technology received 510(k) marketing clearance from the Food and Drug Administration in June 2002 and is available commercially in the United States.

About CHF Solutions

CHF Solutions, based in Brooklyn Park, Minn., is a privately held manufacturer of innovative medical devices for cardiac care. The company's mission is to provide medical practitioners with innovative and practical solutions that enable the treatment of patients with unmet clinical needs. For additional information about CHF Solutions, Aquapheresis, and the Aquadex System 100, visit www.chfsolutions.com.